nach oben

Indian Journal of Hematology and Blood Transfusion

Erschienen in:

02.07.2018 | Original Article

MYD88 and CXCR4 Mutation Profiling in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinaemia

verfasst von: Sushant Vinarkar, Neeraj Arora, Sourav Sarma Chowdhury, Kallol Saha, Biswajoy Pal, Mayur Parihar, Vivek S. Radhakrishnan, Anupam Chakrapani, Shilpa Bhartia, Saurabh Bhave, Mammen Chandy, Reena Nair, Deepak Kumar Mishra

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Recurrent mutations affecting MYD88 and CXCR4 gene nowadays form the basis for the diagnosis, risk stratification and use of inhibitors targeting these signalling pathways in LPL/WM which are rare B cell neoplasms. MYD88 L265P mutation analysis was performed on 33 cases of LPL/WM by AS-PCR (positivity-84.8%, n = 28/33) and by Sanger sequencing (positivity-39.3%, n = 13/33). We had only two cases with CXCR4 non-sense (NS) mutation (p.S338*) using Sanger sequencing. MYD88 (L265P) mutation detection by AS-PCR can form reliable biomarker for the diagnosis of LPL/WM in molecular labs. Although the cohort is small, still the CXCR4 mutation frequency in our study is low as compared to the published literature.

Stein HM-HH, Muller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H (2008) Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Swerdlow S, Campo E, Harris NL et al (eds) International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissue, 4th edn. World Health Organization, Geneva, pp 180–182

Rossi D (2014) Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis. ASH Educ Program Book 2014(1):113–118

Oza A, Rajkumar SV (2015) Waldenstrom macroglobulinemia: prognosis and management. Blood Cancer J 5(3):e394CrossRefPubMed

Ondrejka SL, Lin JJ, Warden DW, Durkin L, Cook JR, Hsi ED (2013) MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders. Am J Clin Pathol 140(3):387–394CrossRefPubMed

Naderi N, Yang DT (2013) Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. Arch Pathol Lab Med 137(4):580–585CrossRefPubMed

Gertz MA (2015) Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management. Am J Hematol 90(4):346–354CrossRefPubMed

Nagao T, Oshikawa G, Ishida S, Akiyama H, Umezawa Y, Nogami A et al (2015) A novel MYD88 mutation, L265RPP, in Waldenström macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival. Blood Cancer J 5(5):e314CrossRefPubMedPubMedCentral

Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al (2012) MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med 367(9):826–833CrossRefPubMed

Yan Q, Huang Y, Watkins AJ, Kocialkowski S, Zeng N, Hamoudi RA et al (2012) BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica 97(4):595–598CrossRefPubMedPubMedCentral

10.

Poulain S, Roumier C, Decambron A et al (2013) MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 121(22):4504–4511CrossRefPubMed

11.

Jiménez C, Sebastián E, Chillón MC et al (2013) MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom’s macroglobulinemia. Leukemia 27(8):1722–1728CrossRefPubMed

12.

Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al (2014) The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 123(11):1637–1646CrossRefPubMed

13.

Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR (2014) Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia. Blood 123(18):2791–2796CrossRefPubMed

14.

García-Sanz R (2016) WM, MYD88, and CXCR4: following the thread. Blood 128(6):746–748CrossRefPubMed

15.

Hunter ZR, Xu L, Yang G, Tsakmaklis N, Vos JM, Liu X et al (2016) Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood 128(6):827–838CrossRefPubMedPubMedCentral

16.

Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R et al (2013) Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms. Blood 121(13):2522–2528CrossRefPubMed

17.

Deshpande P, Mascarenhas R, Subramanian PG, Tembhare P, Bagal B, Gujral S et al (2013) MYD88 negative Waldenstrom macroglobulinemia has distinct clinical and biological features as compared to its MYD88 mutant counterpart. Blood 122(21):4299

18.

Hunter ZR, Yang G, Xu L, Liu X, Castillo JJ, Treon SP (2017) Genomics, signaling, and treatment of Waldenström macroglobulinemia. J Clin Oncol 35(9):994–1001CrossRefPubMed

19.

Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR et al (2010) Comparison of sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations. J Mol Diagn JMD 12(4):425–432CrossRefPubMed

20.

Martinez-Lopez A, Curiel-Olmo S, Mollejo M, Cereceda L, Martinez N, Montes-Moreno S et al (2015) MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma. Am J Surg Pathol 39(5):644–651CrossRefPubMed

21.

Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F et al (2003) Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 34(1):70–74CrossRefPubMed

22.

Liu Q, Chen H, Ojode T, Gao X, Anaya-O’Brien S, Turner NA et al (2012) WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4. Blood 120(1):181–189CrossRefPubMedPubMedCentral

23.

Liu Q, Pan C, Lopez L, Gao J, Velez D, Anaya-O’Brien S et al (2016) WHIM syndrome caused by Waldenström’s macroglobulinemia-associated mutation CXCR4L329fs. J Clin Immunol 36(4):397–405CrossRefPubMed

Titel: MYD88 and CXCR4 Mutation Profiling in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinaemia
verfasst von: Sushant Vinarkar
Neeraj Arora
Sourav Sarma Chowdhury
Kallol Saha
Biswajoy Pal
Mayur Parihar
Vivek S. Radhakrishnan
Anupam Chakrapani
Shilpa Bhartia
Saurabh Bhave
Mammen Chandy
Reena Nair
Deepak Kumar Mishra
Publikationsdatum: 02.07.2018
Verlag: Springer India
Erschienen in: Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2019
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-018-0978-1

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

MYD88 and CXCR4 Mutation Profiling in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinaemia

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Autoimmune Hemolytic Anemia, Erythrophagocytosis and Liver Dysfunction After Cefixime Use for Urinary Tract Infection in a Child

Neutrophilic Erythrophagocytosis in MDS-MLD

Outcomes of Oral Metronomic Therapy in Patients with Lymphomas

Red Cell Indices and Hemoglobin Profile of Newborn Babies with Both the Sickle Gene and Alpha Thalassaemia in Central India

A Case of Anastrozole-Induced Erythrocytosis

Production of Universal Group O Red Blood Cells by Alpha-N-Acetylgalactosaminidase Enzyme Expressed in Pichia pastoris

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie